Drugmaker Cipla’s profit after tax stood at ₹299 crore for the three months ended September 30. It had clocked a profit after tax of ₹358 crore in the corresponding period in the previous fical.

The current figures include the relevant results of Cipla’s subsidiaries from the date they became subsidiaries of the company and therefore the corresponding figures for the previous period were not comparable, a Cipla note said.

The company clocked net sales of ₹2,630 crore in the period under review. Its domestic sales stood at ₹1,251 crore during Q2 FY 2014-15, on the back of pediatrics, respiratory, spectracare and urology therapies. Cipla’s export of formulations stood at ₹1,243 crore during the period under review. However, export of active pharmaceutical ingredients declined to ₹136 crore during the quarter from ₹206 crore during the corresponding period last fiscal, Cipla said. Meanwhile, Cipla announced the appointment of Punita Lal and Nachiket Mor as independent directors on its board effective 13th November. In her last role, Punita Lal was the Chief Executive of NourishCo, a J-V between PepsiCo and Tatas. Mor is at present on the Board of CRISIL Limited as an independent director and also serves on the Boards of the IKP Trust and CARE India.